Status:
UNKNOWN
Clinical Characterization and Outcome of Anti-IgLON5 Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Anti-IgLON5 Disease
Eligibility:
All Genders
18+ years
Brief Summary
Anti-IgLON5 disease is a neurological disorder associated with antibodies to IgLON5, a neuronal cell adhesion protein of unknown function. Most patients develop a combination of significant sleep dist...
Eligibility Criteria
Inclusion
- Patients \> 18 ans
- Anti-IgLON5 antibody positivity
Exclusion
- \- Lack of clinical data
Key Trial Info
Start Date :
February 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06131346
Start Date
February 23 2023
End Date
December 31 2023
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Bron, France, 69677